A Phase 4 interventional study of Pregabalin and Placebo in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 13 sites in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being performed as a Phase IV FDA commitment study and is being powered adequately to assess changes in sperm concentration, FSH and testosterone in healthy male subjects treated with pregabalin as compared to placebo, in addition to confirming lack of effects on sperm motility.
This is a Phase 4 FDA commitment study. The purpose of the study is to evaluate the effects of pregabalin as compared to placebo on sperm concentration in healthy male subjects
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Pregabalin
Drug: Placebo
pregabalin 600 mg given twice a day
Placebo
Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS)
Baseline is the average of sperm concentrations from semen samples collected on or before Study Day 1. End of study is average of sperm concentrations from semen samples collected at end of washout period (Week 26) following 12 weeks of double-blind treatment. Mean sperm concentration (MSC) of a visit is average of the 2 sperm concentration samples collected at that visit. If sperm concentration was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead. Confidence intervals (CI) based on exact distribution.
Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Change From Baseline in Follicle Stimulating Hormone (FSH) to End of Study (EOS)
FSH minimum normal range 1.4 International units per liter (IU/L) to maximum normal range 18.1 IU/L. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.
Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Change From Baseline in Follicle Stimulating Hormone (FSH) to Week 26
FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.
Time frame: Baseline, Week 26 (last observation in the Week 26 window)
Change From Baseline in Follicle Stimulating Hormone (FSH) to Week 12
FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.
Time frame: Baseline, Week 12 (last observation in the Week 12 window)
Change From Baseline in Testosterone to End of Study (EOS)
End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.
Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Change From Baseline in Testosterone to Week 26
Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.
Time frame: Baseline, Week 26 (last observation in the Week 26 window)
Change From Baseline in Testosterone to Week 12
Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.
Time frame: Baseline, Week 12 (last observation in the Week 12 window)
Change From Baseline in Sperm Motility to End of Study (EOS)
Mean sperm motility (percent motility representing grade a+b \[a=sperm with progressive, straight-line motility; b=non-linear motility\]) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.
Time frame: Baseline, End of Study (last observation at Week 26 or last assessment on or after Week 12 if no data at Week 26)
Change From Baseline in Sperm Motility to Week 26
Mean sperm motility (percent motility representing grade a+b) was the average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 26 was average of the last 2 values within window of 134 to 252 days from Study Day 1 and at least 1 of the 2 values was non-missing. If only 1 assessment date within the stated window, Week 26 was the value of that single assessment. If all values within window were missing, the records were not to be used for Week 26 analysis.
Time frame: Baseline, Week 26 (last observation in the Week 26 window)
Change From Baseline in Sperm Motility to Week 12
Mean sperm motility (percent motility representing grade a+b) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 12 was average of last 2 values within window of 2 to 133 days from Study Day 1 and at least 1 of the 2 values was non-missing. If there was only 1 assessment date within the stated window, then Week 12 was the value of that single assessment. If all the values within the window were missing, then the records were not to be used for Week 12 analysis.
Time frame: Baseline, Week 12 (last observation in the Week 12 window)
Study was conducted at 12 centers in the United States between February 2008 and February 2012; 903 participants were screened and 222 were assigned to study treatment.
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 112 | 110 |
| Received study treatment (tx) | 111 | 109 |
| Ongoing at database release 18oct2011 | 2 | 0 |
| Completed | 75 | 70 |
| Not completed | 37 | 40 |
| Withdrew: Entered, not randomized to treatment | 1 | 1 |
| Withdrew: Discontinued after database release date | 1 | 0 |
| Withdrew: Follow up after database release date | 1 | 0 |
| Withdrew: Lost to follow-up | 7 | 10 |
| Withdrew: Withdrawal by subject | 2 | 9 |
| Withdrew: Other | 8 | 8 |
| Withdrew: Protocol violation | 9 | 9 |
| Withdrew: Study terminated by sponsor | 3 | 3 |
| Withdrew: Adverse event | 5 | 0 |
Baseline is the average of sperm concentrations from semen samples collected on or before Study Day 1. End of study is average of sperm concentrations from semen samples collected at end of washout period (Week 26) following 12 weeks of double-blind treatment. Mean sperm concentration (MSC) of a visit is average of the 2 sperm concentration samples collected at that visit. If sperm concentration was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead. Confidence intervals (CI) based on exact distribution.
| percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS) | 9.2 (3.46 to 19.02) | 3.2 (0.39 to 11.17) |
FSH minimum normal range 1.4 International units per liter (IU/L) to maximum normal range 18.1 IU/L. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.
| IU/L | Pregabalin | Placebo |
|---|---|---|
| Baseline | 3.17 ± 1.624 | 3.68 ± 1.997 |
| Change to EOS | 0.14 ± 0.746 | 0.22 ± 0.953 |
FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.
| IU/L | Pregabalin | Placebo |
|---|---|---|
| Baseline | 3.20 ± 1.685 | 3.69 ± 2.050 |
| Change to Week 26 | 0.16 ± 0.757 | 0.21 ± 0.949 |
FSH minimum normal range 1.4 IU/L to maximum normal range 18.1 IU/L. Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.
| IU/L | Pregabalin | Placebo |
|---|---|---|
| Baseline | 3.17 ± 1.624 | 3.68 ± 1.997 |
| Change to Week 12 | -0.05 ± 0.785 | 0.08 ± 0.974 |
End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.
| nanograms per deciliter (ng/dL) | Pregabalin | Placebo |
|---|---|---|
| Baseline | 518.2 ± 179.13 | 481.8 ± 171.07 |
| Change to EOS | 10.4 ± 170.78 | 0.8 ± 150.64 |
Week 26 was the non-missing value within 134 to 252 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 26 analysis.
| ng/dL | Pregabalin | Placebo |
|---|---|---|
| Baseline | 517.9 ± 182.34 | 474.6 ± 167.09 |
| Change to Week 26 | 13.8 ± 171.37 | 2.6 ± 146.80 |
Week 12 was the last non-missing value within 2 to 133 days from Study Day 1. If there were multiple observations between the stated study days (all non-missing or a combination of missing and non-missing), then the latest non-missing value was selected for analysis. If all the values within the stated window were missing, then the records were not to be used for Week 12 analysis.
| ng/dL | Pregabalin | Placebo |
|---|---|---|
| Baseline | 518.2 ± 179.13 | 481.8 ± 171.07 |
| Change to Week 12 | -14.8 ± 169.56 | 0.0 ± 123.61 |
Mean sperm motility (percent motility representing grade a+b \[a=sperm with progressive, straight-line motility; b=non-linear motility\]) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. End of study was the end of the washout period (Week 26) following 12 weeks of double-blind treatment. If the semen parameter was not assessed at Week 26, then the last assessment on or after Week 12 (end of treatment) was used instead.
| percent motility | Pregabalin | Placebo |
|---|---|---|
| Baseline | 61.9 ± 9.98 | 61.4 ± 8.32 |
| Change to EOS | -3.2 ± 10.57 | -1.8 ± 7.49 |
Mean sperm motility (percent motility representing grade a+b) was the average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 26 was average of the last 2 values within window of 134 to 252 days from Study Day 1 and at least 1 of the 2 values was non-missing. If only 1 assessment date within the stated window, Week 26 was the value of that single assessment. If all values within window were missing, the records were not to be used for Week 26 analysis.
| percent motility | Pregabalin | Placebo |
|---|---|---|
| Baseline | 61.8 ± 10.46 | 61.2 ± 8.71 |
| Change to Week 26 | -2.6 ± 9.71 | -1.8 ± 6.52 |
Mean sperm motility (percent motility representing grade a+b) was average of 2 samples collected at that visit. Normal value is ≥50% motility measured within 60 minutes of collection; higher values=greater percentage of sperm with motility. Week 12 was average of last 2 values within window of 2 to 133 days from Study Day 1 and at least 1 of the 2 values was non-missing. If there was only 1 assessment date within the stated window, then Week 12 was the value of that single assessment. If all the values within the window were missing, then the records were not to be used for Week 12 analysis.
| percent motility | Pregabalin | Placebo |
|---|---|---|
| Baseline | 61.95 ± 9.976 | 61.38 ± 8.316 |
| Change to Week 12 | -3.94 ± 8.570 | -2.71 ± 8.186 |
Collected over Treatment emergent Adverse Events are collected from the time of first dose of study treatment through last subject last visit (06 February 2012).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 0/111 (0%) | 43/111 (38.7%) |
| Placebo | — | 0/109 (0%) | 18/109 (16.5%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 21/111 | 1/109 |
| SomnolenceNervous system disorders | 11/111 | 5/109 |
| Euphoric moodPsychiatric disorders | 6/111 | 1/109 |
| HeadacheNervous system disorders | 4/111 | 5/109 |
| FatigueGeneral disorders | 5/111 | 1/109 |
| NauseaGastrointestinal disorders | 2/111 | 4/109 |
| Muscle strainInjury, poisoning and procedural complications | 4/111 | 1/109 |
| ParaesthesiaNervous system disorders | 4/111 | 1/109 |
| Age, Customized(participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Between 18 and 44 years | 100 | 93 | 193 |
| Between 45 and 64 years | 11 | 16 | 27 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 111 | 109 | 220 |
The record gives a start of Feb 2008, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →